CN104983878A - Chinese herba preparation for treating acro-arteriosclerosis obliterans and preparation method thereof - Google Patents
Chinese herba preparation for treating acro-arteriosclerosis obliterans and preparation method thereof Download PDFInfo
- Publication number
- CN104983878A CN104983878A CN201510497923.7A CN201510497923A CN104983878A CN 104983878 A CN104983878 A CN 104983878A CN 201510497923 A CN201510497923 A CN 201510497923A CN 104983878 A CN104983878 A CN 104983878A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- preparation
- medicine preparation
- arteriosclerosis obliterans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine and particularly relates to a Chinese herba preparation for treating acro-arteriosclerosis obliterans and a preparation method thereof. The Chinese herba preparation is made of astragalus membranaceus, codonopsis pilosula, red-rooted salvia roots, moutan bark, loofa sponge, caulis spatholobi, houttuynia cordata, houttuynia cordata, seaweed and oysters. The Chinese herba preparation is remarkably effective in promoting the blood circulation, removing the blood stasis, inducing menstruation, reliving menalgia, tonifying qi and regulating the vital energy, a good therapeutic effect for treating the acro-arteriosclerosis obliterans, in particular to the blood stasis type acro-arteriosclerosis obliterans, is achieved, the medicine side effect is little, relapse is not prone to occurring, and the significant clinic promotion value is achieved.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind ofly treat Chinese medicine preparation of acra atherosclerotic occlusive disease and preparation method thereof.
Background technology
Acra atherosclerotic occlusive disease is the continuous expansion of medicated porridge sample material in limb artery and secondary thrombus is formed, cause ductus arteriosus wall narrow, inaccessible, limbs are made to occur a kind of disease that is chronic or acute ischemia symptom, main manifestations be limbs cool, numb, bitterly, moving obstacle even ulcer, gangrene etc., wherein common with lower limb.This sick early symptom does not show, and easily ignores, until late period, not easily cures, disables, fatality rate is higher, and patient is painful large, and medical expense is high, brings white elephant to patient family and society.Along with the development of society, the quickening of rhythm of life, the factors such as social senilization, diet, spiritual feelings will are in the orthobiosis day by day affecting the people, and the morbidity of acra atherosclerotic occlusive disease is obvious ascendant trend, become one of principal disease of the life of harm middle-aged and elderly people and life.
Acra arteriosclerosis obliterans belongs to the traditional Chinese medical science " necrosis ", categories such as " quenching one's thirst ".The traditional Chinese medical science thinks its mechanism many due to illness man-years height weakness of QI, movement of QI being out of order, and the venation stasis of blood is stagnant, and through flow of QI being obstructed, vital QI being weakened and pathogen being violent, the evil stasis of blood is tied mutually, stasis of blood heat-transformation of a specified duration, and the corruption of intenseness of heat meat forms primary disease, is the card of deficiency in origin and excess in superficiality, is negative and positive of qi and blood virtual loss, is being designated as obstruction of collaterals by blood stasis at this.
Along with improving constantly of medical level and continuing to bring out of new technique, the Therapeutic Method of atherosclerotic occlusive disease gets more and more, especially in recent years along with the development of surgical technic and interventional technique, operation, interventional therapy has become one of main treatment section of acra atherosclerotic occlusive disease.But, it is also the most frequently used Therapeutic Method that Drug therapy remains acra atherosclerotic occlusive disease first-selection, through the treatment of acra atherosclerotic occlusive disease all the time, particularly Chinese Traditional Medicine has long history and rich experience in control acra atherosclerotic occlusive disease, curative effect certainly, without obvious toxic-side effects, relapse rate is low, and late result is good.Therefore, the Chinese medicine preparation developing the more definite treatment acra atherosclerotic occlusive disease of curative effect is necessary.
Summary of the invention
In order to solve the problem, the present invention aims to provide and a kind ofly treats Chinese medicine preparation of acra arteriosclerosis obliterans and preparation method thereof.
An object of the present invention is to provide a kind of Chinese medicine preparation for the treatment of acra arteriosclerosis obliterans.
Another object of the present invention is to provide the preparation method of the Chinese medicine preparation of a kind of acra arteriosclerosis obliterans.
Chinese medicine preparation of the present invention is obtained by following crude drug: the Radix Astragali, Radix Codonopsis, Radix Salviae Miltiorrhizae, Cortex Moutan, Retinervus Luffae Fructus, Caulis Spatholobi, Herba Houttuyniae, Fructus Forsythiae, Sargassum, Concha Ostreae.
Preferably, its active ingredient is made up of the crude drug of following weight portion: Radix Astragali 16-18 part, Radix Codonopsis 6-8 part, Radix Salviae Miltiorrhizae 8-10 part, Cortex Moutan 7-9 part, Retinervus Luffae Fructus 12-14 part, Caulis Spatholobi 10-12 part, Herba Houttuyniae 6-8 part, Fructus Forsythiae 8-10 part, Sargassum 8-10 part, Concha Ostreae 5-8 part.
The present invention most preferably its active ingredient is made up of the crude drug of following weight portion: the Radix Astragali 17 parts, Radix Codonopsis 7 parts, Radix Salviae Miltiorrhizae 9 parts, Cortex Moutan 8 parts, Retinervus Luffae Fructus 13 parts, Caulis Spatholobi 11 parts, Herba Houttuyniae 7 parts, Fructus Forsythiae 9 parts, Sargassum 9 parts, Concha Ostreae 6 parts.
The Chinese medicine preparation that the present invention treats acra arteriosclerosis obliterans can also contain pharmaceutically acceptable carrier, is prepared into conventional formulation, as capsule, tablet or granule, is preferably granule.
The preparation method of Chinese medicine preparation of the present invention comprises the steps: that the crude drug of above-mentioned weight portion pulverized 80 mesh sieves respectively, mix homogeneously, add the soak by water 2 times of medical material gross mass 5 times amount, each 2 hours, filter cleaner extracting juice merges, and when the filtrate after merging is concentrated into 75 DEG C, its relative density is the clear paste of 1.11-1.18, to add again after drying and crushing on pharmaceutics acceptable adjuvant routinely technique be prepared into required preparation.
Chinese medicine preparation of the present invention, has the following advantages and effect:
(1) mainly according to acra arteriosclerosis obliterans, this is negative and positive of qi and blood virtual loss to Chinese medicine preparation prescription of the present invention, and the pathogenic characteristic being designated as obstruction of collaterals by blood stasis develops.Syndrome analysis for acra arteriosclerosis obliterans particularly blood stasis type acra arteriosclerosis obliterans: suffering limb is numb, and send out cool, pain is fixed, lasting, the visible ecchymosis of acra, foot color of the leather cyanosis, limping increases the weight of, and can occur rest pain at night, dark tongue quality, visible ecchymosis, stringy and hesitant pulse.The Radix Astragali in side, Radix Codonopsis, invigorating QI to consolidate the body surface resistance, spleen invigorating lung benefiting; Cortex Moutan, Radix Salviae Miltiorrhizae, Retinervus Luffae Fructus, Caulis Spatholobi, enriches blood and invigorates blood circulation, and blood stasis dispelling is stimulated the menstrual flow; Herba Houttuyniae, Fructus Forsythiae, heat-clearing and toxic substances removing, dispersing swelling and dissipating binds; Sargassum, Concha Ostreae, hard masses softening and resolving, reduce phlegm diuretic.Full side plays blood circulation promoting and blood stasis dispelling altogether, inducing menstruation to relieve menalgia, the merit that QI invigorating is regulated the flow of vital energy, to acra arteriosclerosis obliterans particularly blood stasis type acra arteriosclerosis obliterans have extremely strong specific aim curative effect, onset is rapid, treating both the principal and secondary aspects of a disease.
(2) Chinese medicine preparation of the present invention is when acra arteriosclerosis obliterans for chemical drugs, and untoward reaction and few side effects, not easily recur.
(3) through clinical practice checking, use invention formulation treatment blood stasis type acra arteriosclerosis obliterans, effective 31 examples of the routine patient for the treatment of group 60, effective 25 examples, total effective rate 95%, clinical effectiveness is very remarkable.
The functional effect of Chinese medicine preparation of the present invention each Chinese medicine component is as follows:
The Radix Astragali, warm in nature, sweet in the mouth.Invigorating QI to consolidate the body surface resistance, expelling pus and toxin by strengthening QI, diuresis, granulation promoting., chronic diarrhea proctoptosis, spontaneous perspiration, edema weak for the deficiency of vital energy, sub-official prolapsus, chronic nephritis proteinuria, diabetes, open sore part disunion of a specified duration.
Radix Codonopsis, sweet, flat.Return spleen, lung meridian.Invigorating the spleen and replenishing QI, spleen invigorating lung benefiting.For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Radix Salviae Miltiorrhizae, bitter, be slightly cold.GUIXIN, Liver Channel.Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, clear away heart-fire relieving restlessness.For menoxenia, amenorrhea dysmenorrhea ， lumps in the chest and abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, angina pectoris.
Cortex Moutan, bitter, pungent, be slightly cold.GUIXIN, liver, kidney channel.Clearing away heat and cooling blood, blood circulation promoting and blood stasis dispelling.For maculae caused by violent heat pathogen, hematemesis and epistaxis, night fever abating at dawn, lossless hectic fever due to YIN-deficiency, amenorrhea dysmenorrhea, carbuncle sore tumefacting virus, falls and flutters the pain of injury.
Retinervus Luffae Fructus, sweet, flat.Return lung, stomach, Liver Channel.Dredging collateral, invigorates blood circulation, and dispels the wind.For arthralgia pain contracture, distending pain in the chest and hypochondrium, galactostasis.
Caulis Spatholobi, bitter, sweet, temperature.Return liver, kidney channel.Enrich blood, invigorate blood circulation, dredging collateral.For menoxenia, blood deficiency and yellow complexion, paralysis and numbness, rheumatic arthralgia.
Herba Houttuyniae, pungent, be slightly cold.Return lung meridian.Heat-clearing and toxic substances removing, eliminating carbuncle evacuation of pus, inducing diuresis for treating stranguria syndrome.For lung abscess vomiting pus, expectorant dyspnea of heat type is coughed, hematodiarrhoea, pyretic stranguria, carbuncle sore tumefacting virus.
Fructus Forsythiae, bitter, be slightly cold.Return lung, the heart, small intestine meridian.Heat-clearing and toxic substances removing, dispersing swelling and dissipating binds.For carbuncle, scrofula, acute mastitis, erysipelas, anemopyretic cold, epidemic febrile disease from the beginning of, warmly join the army, high hot excessive thirst, coma sends out speckle, pyretic stranguria urine retention.
Sargassum is bitter, salty, cold.Return liver, stomach, kidney channel.Hard masses softening and resolving, expectorant, diuretic.For goiter, scrofula, painful and swollen testis, phlegm retention edema.
Concha Ostreae, salty, be slightly cold.Return liver, gallbladder, kidney channel.Tranquillization with heavy prescription, YANG hyperactivity suppressing nourishing YIN, hard masses softening and resolving.For insomnia of palpitating with fear, vertigo and tinnitus, scrofula sucutaneous nodule ， mass in the abdomen mass in the abdomen.Concha Ostreae (calcined) convergence is astringent or styptic treatment for spontaneous sweating.For spontaneous sweating, seminal emission metrorrhagia and leukorrhagia, stomachache acid regurgitation.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Embodiment 1 capsule
Each raw material is taken: the Radix Astragali 17 parts, Radix Codonopsis 7 parts, Radix Salviae Miltiorrhizae 9 parts, Cortex Moutan 8 parts, Retinervus Luffae Fructus 13 parts, Caulis Spatholobi 11 parts, Herba Houttuyniae 7 parts, Fructus Forsythiae 9 parts, Sargassum 9 parts, Concha Ostreae 6 parts by following weight portion.
Preparation method: the crude drug of above-mentioned weight portion pulverized 80 mesh sieves respectively, mix homogeneously, add the soak by water 2 times of medical material gross mass 5 times amount, each 2 hours, filter cleaner extracting juice merges, and when the filtrate after merging is concentrated into 75 DEG C, its relative density is the clear paste of 1.11-1.18, and crushed after being dried crosses 80 mesh sieves, then adds pharmaceutically acceptable adjuvant, mix homogeneously, conveniently preparation technology is prepared into capsule.
When using Chinese medicine preparation acra arteriosclerosis obliterans of the present invention, take prepared capsule, every contains crude drug amount 0.15g, every day 3 times, each 3-4 grain.
Embodiment 2 tablet
Each raw material is taken: the Radix Astragali 17 parts, Radix Codonopsis 7 parts, Radix Salviae Miltiorrhizae 9 parts, Cortex Moutan 8 parts, Retinervus Luffae Fructus 13 parts, Caulis Spatholobi 11 parts, Herba Houttuyniae 7 parts, Fructus Forsythiae 9 parts, Sargassum 9 parts, Concha Ostreae 6 parts by following weight portion.
Preparation method: the crude drug of above-mentioned weight portion pulverized 80 mesh sieves respectively, mix homogeneously, add the soak by water 2 times of medical material gross mass 5 times amount, each 2 hours, filter cleaner extracting juice merges, and when the filtrate after merging is concentrated into 75 DEG C, its relative density is the clear paste of 1.11-1.18, and crushed after being dried crosses 80 mesh sieves, then adds pharmaceutically acceptable adjuvant, mix homogeneously, conveniently preparation technology is prepared into tablet.
When using Chinese medicine preparation acra arteriosclerosis obliterans of the present invention, take prepared tablet, every sheet contains crude drug amount 0.15g, every day 3 times, each 3-4 sheet.
Embodiment 3 granule
Each raw material is taken: the Radix Astragali 17 parts, Radix Codonopsis 7 parts, Radix Salviae Miltiorrhizae 9 parts, Cortex Moutan 8 parts, Retinervus Luffae Fructus 13 parts, Caulis Spatholobi 11 parts, Herba Houttuyniae 7 parts, Fructus Forsythiae 9 parts, Sargassum 9 parts, Concha Ostreae 6 parts by following weight portion.
Preparation method: the crude drug of above-mentioned weight portion pulverized 80 mesh sieves respectively, mix homogeneously, add the soak by water 2 times of medical material gross mass 5 times amount, each 2 hours, filter cleaner extracting juice merges, and when the filtrate after merging is concentrated into 75 DEG C, its relative density is the clear paste of 1.11-1.18, and crushed after being dried crosses 80 mesh sieves, then adds pharmaceutically acceptable adjuvant, mix homogeneously, conveniently preparation technology is prepared into granule.
When using Chinese medicine preparation acra arteriosclerosis obliterans of the present invention, take prepared granule, every bag contains crude drug amount 0.5g, every day 3 times, each 1 bag.
Embodiment 4 granule
Each raw material is taken: the Radix Astragali 16 parts, Radix Codonopsis 6 parts, Radix Salviae Miltiorrhizae 8 parts, Cortex Moutan 7 parts, Retinervus Luffae Fructus 12 parts, Caulis Spatholobi 10 parts, Herba Houttuyniae 6 parts, Fructus Forsythiae 8 parts, Sargassum 8 parts, Concha Ostreae 5 parts by following weight portion.
Preparation technology is with embodiment 3.
Embodiment 5 granule
Each raw material is taken: the Radix Astragali 18 parts, Radix Codonopsis 8 parts, Radix Salviae Miltiorrhizae 10 parts, Cortex Moutan 9 parts, Retinervus Luffae Fructus 14 parts, Caulis Spatholobi 12 parts, Herba Houttuyniae 8 parts, Fructus Forsythiae 10 parts, Sargassum 10 parts, Concha Ostreae 8 parts by following weight portion.
Preparation technology is with embodiment 3.
The clinical observation of embodiment 6 Chinese medicine preparation acra of the present invention arteriosclerosis obliterans
1, case-data: that selects hospital ward and outpatient clinic meets blood stasis type acra arteriosclerosis obliterans patient 120 example, the oldest 80 years old, minimum 45 years old, 63.2 years old mean age; The course of disease 3 months-6 years, average course of disease 3 years, is associated with hyperpietic 45 example, coronary disease patient 27 example, diabetes 48 example.Be divided into treatment group, matched group at random.Wherein, in the routine patient for the treatment of group 60, man 38 example, female 22 example; In the routine patient of matched group 60, man 40 example, female 20 example.The physical data there was no significant differences such as two groups of Genders, age, courses of disease, have comparability.
2, diagnosis basis:
120 routine patients all meet following standard: 1. with reference to the diagnostic criteria that " atherosclerotic occlusive disease " is formulated, all clarified a diagnosis as arterial occlusion of lower extremities; Tcm diagnosis blood stasis type acra arteriosclerosis obliterans disease is seen: suffering limb is numb, and send out cool, pain is fixed, and continue, the visible ecchymosis of acra, foot color of the leather cyanosis, limping increases the weight of, and can occur rest pain at night, dark tongue quality, visible ecchymosis, stringy and hesitant pulse.2. the patient to this institute drug allergy is got rid of; Complete and there is the patient of severe infections with severe cardiac, Liver and kidney function; There is the patient of severe psychiatric, dysnoesia.
3, standard is rejected:
1. above-mentioned inclusive criteria is not met and by the case included in by mistake.
Although 2. meet above-mentioned inclusive criteria, include rear untreated case in.
4, come off standard:
1. the therapeutic scheme person that can not adhere to being in harmony treatment scheme or automatically abandoning regulation is studied in observation process.
2. the judgement persons that affect the treatment such as in research process the complete or patient compliance of discovery data is poor.
3. there is serious adverse events in research process, the person that should not continue reception test.
4. in research process conditions of patients change, or because of other reasons can not continue accept and completed treatment person.
5, Therapeutic Method:
All selected patients all give conventional therapy, and (give up smoking, keep on a diet, be combined hypertension, diabetes, coronary disease patient, control blood pressure, blood glucose, blood fat is in desirable level.)
Matched group is oral aspirin medicament for resisting platelet aggregation on basis of conventional therapy, and alprostadil injection 10 μ g adds 0.9% sodium chloride injection 150mL and instils, 1 time/d.
The Granules in Treating that treatment group selects embodiment 3 to prepare on basis of conventional therapy, every bag contains crude drug amount 0.5g, every day 3 times, each 1 bag.
Two groups of equal 15d were 1 course for the treatment of, after treating 2 courses for the treatment of, carried out short-term evaluation.
6, curative effect determinate standard: the criterion of therapeutical effect of limb artery sclerosis obliterans formulated of Professional Committee can formulate following evaluation of clinical curative effect standard with reference to All-China Association of Traditional Chinese Medicine vascular: 1. effective: clinical symptoms disappears completely or comparatively has clear improvement before treatment, wound surface heals or close healing completely, rheography takes a turn for the better completely with comparing before treatment or is improved, and walk lamely the above person of distance 1000m; 2. effective: clinical symptom relief, wound surface reduces before comparatively treating, and rheography makes moderate progress, and walk lamely about distance 500m; 3. invalid: clinical symptoms and sign increase the weight of before being not improved or comparatively treating.
Total effective rate is obvious effective rate+effective percentage.
7, therapeutic outcome:
In clinical observation process, 120 routine patients all complete clinical observation.Effective 31 examples of the routine patient for the treatment of group 60, effective 25 examples, invalid 4 examples, total effective rate 95%, clinical effectiveness is remarkable; Effective 22 examples of the routine patient of matched group 60, effective 23 examples, invalid 15 examples, total effective rate 77.5%, two groups of total effective rates compare, and have significant difference, observation group is significantly better than matched group.
Two groups of symptom comparitive study
| Group | n | Effective | Obvious effective rate | Effectively | Invalid | Total effective rate |
| Treatment group | 60 | 34 | 56.7％ | 22 | 4 | 56(93.3％) |
| Matched group | 60 | 22 | 36.7％ | 23 | 15 | 45(75％) |
Clinical observation result shows, and treatment group symptom obvious effective rate, total effective rate are all obviously better than matched group, and this Chinese medicine preparation improves obviously acra arteriosclerosis obliterans clinical symptoms as seen.Simultaneously in safety evaluatio, the routine blood test before and after treatment group patient consumes, routine urinalysis etc. inspections do not find obvious exception.Illustrate that using Chinese medicine preparation of the present invention treatment acra arteriosclerosis obliterans particularly to treat belongs to blood stasis type acra arteriosclerosis obliterans determined curative effect thus, safe and reliable, can be used as the effective ways for the treatment of blood stasis type acra arteriosclerosis obliterans, be worth of widely use in clinical.
Claims (8)
1. the Chinese medicine preparation of an acra arteriosclerosis obliterans, it is characterized in that, it is obtained by the crude drug of following weight portion: Radix Astragali 16-18 part, Radix Codonopsis 6-8 part, Radix Salviae Miltiorrhizae 8-10 part, Cortex Moutan 7-9 part, Retinervus Luffae Fructus 12-14 part, Caulis Spatholobi 10-12 part, Herba Houttuyniae 6-8 part, Fructus Forsythiae 8-10 part, Sargassum 8-10 part, Concha Ostreae 5-8 part.
2. Chinese medicine preparation as claimed in claim 1, it is characterized in that, it is obtained by the crude drug of following weight portion: the Radix Astragali 17 parts, Radix Codonopsis 7 parts, Radix Salviae Miltiorrhizae 9 parts, Cortex Moutan 8 parts, Retinervus Luffae Fructus 13 parts, Caulis Spatholobi 11 parts, Herba Houttuyniae 7 parts, Fructus Forsythiae 9 parts, Sargassum 9 parts, Concha Ostreae 6 parts.
3. the Chinese medicine preparation as described in any one of claim 1-2, it is also containing pharmaceutically acceptable carrier.
4. Chinese medicine preparation as claimed in claim 3, it is characterized in that, described Chinese medicine preparation is capsule, tablet or granule.
5. Chinese medicine preparation as claimed in claim 4, is characterized in that, described Chinese medicine preparation preferably granule.
6. one kind prepare as arbitrary in claim 1-2 as described in the method for Chinese medicine preparation, it is characterized in that, it comprises the following steps: the crude drug of above-mentioned weight portion pulverized 80 mesh sieves respectively, mix homogeneously, adds the soak by water 2 times of medical material gross mass 5 times amount, each 2 hours, filter cleaner extracting juice merges, and when the filtrate after merging is concentrated into 75 DEG C, its relative density is the clear paste of 1.11-1.18, to add again after drying and crushing on pharmaceutics acceptable adjuvant routinely technique be prepared into required preparation.
7. the purposes of Chinese medicine preparation in the medicine preparing acra arteriosclerosis obliterans as described in claim 1,2.
8. the purposes of the Chinese medicine preparation as described in claim 1,2 in the medicine of preparation treatment blood stasis type acra arteriosclerosis obliterans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510497923.7A CN104983878A (en) | 2015-08-14 | 2015-08-14 | Chinese herba preparation for treating acro-arteriosclerosis obliterans and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510497923.7A CN104983878A (en) | 2015-08-14 | 2015-08-14 | Chinese herba preparation for treating acro-arteriosclerosis obliterans and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104983878A true CN104983878A (en) | 2015-10-21 |
Family
ID=54295867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510497923.7A Pending CN104983878A (en) | 2015-08-14 | 2015-08-14 | Chinese herba preparation for treating acro-arteriosclerosis obliterans and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104983878A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011063546A (en) * | 2009-09-17 | 2011-03-31 | Rohto Pharmaceutical Co Ltd | Pharmaceutical composition |
| CN104688908A (en) * | 2013-12-09 | 2015-06-10 | 青岛百草汇中草药研究所 | Arteriosclerotic obliterans treating traditional Chinese medicine |
-
2015
- 2015-08-14 CN CN201510497923.7A patent/CN104983878A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011063546A (en) * | 2009-09-17 | 2011-03-31 | Rohto Pharmaceutical Co Ltd | Pharmaceutical composition |
| CN104688908A (en) * | 2013-12-09 | 2015-06-10 | 青岛百草汇中草药研究所 | Arteriosclerotic obliterans treating traditional Chinese medicine |
Non-Patent Citations (1)
| Title |
|---|
| 夏军山: "中医内服外治结合治疗动脉硬化性闭塞症65例", 《中国医药指南》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103705603B (en) | Traditional Chinese medicine for treating acne | |
| CN104523865B (en) | Medicine for treating breast diseases | |
| CN104189871A (en) | Medicated wine for treating osteoproliferation | |
| CN103393862B (en) | Chinese medicinal composition for treating lumbocrural pain | |
| CN105079188A (en) | Traditional Chinese medicine composition for treating anaphylactoid purpura | |
| CN103908600B (en) | The external used medicine for the treatment of rheumatoid arthritis damp-heat arthralgia resistance card and preparation method | |
| CN105641256A (en) | Chinese herbal medicine composition for treating chalazion of children | |
| CN105125792A (en) | Traditional Chinese medicinal decoction for treating female mastitis and preparation method of decoction | |
| CN105106498A (en) | Traditional Chinese medicine composition for treating diabetic foot | |
| CN108295128A (en) | A kind of compound Chinese medicinal preparation and preparation method thereof for treating rheumatoid arthritis | |
| CN100546640C (en) | A kind of Chinese medicine composition of orally taken for curing cyclomastopathy | |
| CN103585273B (en) | Traditional Chinese medicine composition for treating local swelling and pain | |
| CN103041085B (en) | Traditional Chinese medicine composition for treating dysmenorrheal by lavipeditum nursing and application | |
| CN105327171A (en) | Traditional Chinese medicine electuary for treating mastitis and preparing method thereof | |
| CN105434739A (en) | Traditional Chinese medicine composition for treating chalazia and preparation method thereof | |
| CN105327290B (en) | A kind of external application Chinese medicine and preparation method thereof for treating diabetic gangrene | |
| CN103893432A (en) | Pharmaceutical composition for treating fracture and soft tissue injury and preparation method of pharmaceutical composition | |
| CN104983878A (en) | Chinese herba preparation for treating acro-arteriosclerosis obliterans and preparation method thereof | |
| CN104474455A (en) | Traditional Chinese medicine for treating hyperthyroidism | |
| CN103638369B (en) | Traditional Chinese medicinal preparation for treating mastitis | |
| CN100406035C (en) | Chinese medicine preparation for treating protrasion of lumbar intervertebral disc | |
| CN102861195B (en) | Drug composition for treating rheumatism pain | |
| CN105194588A (en) | Traditional Chinese medicine preparation for treating liver cirrhosis | |
| CN105232661A (en) | Traditional Chinese medicine composition for treating mastitis and preparation method thereof | |
| CN105943639A (en) | Traditional Chinese medicine composition assisting in treating chronic subdural hematoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151021 |